Elementis PLC Unsponsored ADR AI Stock Analysis
Want to see ELMTY full AI Analyst Report?
Elementis PLC Unsponsored ADR (ELMTY) AI Stock Analysis
Elementis PLC Unsponsored ADR
(Other OTC:ELMTY)
The overall score of 58 reflects a company with a solid financial foundation but persistent profitability challenges. The strongest factor is the conservative balance sheet, which provides stability. This is offset by the income statement's net losses and declining revenue, which are the most significant risks. Technical trends are supportive, and the valuation is fair, but the company's core issue of converting operational performance into sustainable net profit remains the key hurdle.
Elementis PLC Unsponsored ADR (ELMTY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.32B
- Dividend Yield
- 2.33%
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 19.5
- Beta (1Y)
- 0.70
- Revenue Growth
- -8.97%
- EPS Growth
- ―
- Country
- US
- Employees
- 989
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Elementis PLC Unsponsored ADR Business Overview & Revenue Model
Company Description
Elementis plc operates as a specialty chemical company in the United Kingdom, rest of Europe, North America, and internationally. It operates in two segments, Coatings and Personal Care. The Coatings segment offers production of rheological modifiers...
How the Company Makes Money
Elementis makes money primarily by selling specialty chemical additives and formulated ingredients to business customers (B2B). Revenue is generated from (1) product sales into its key end markets—most notably coatings and personal care—where its add...
Elementis PLC Unsponsored ADR Earnings Call Summary
The call emphasized strong profitability, margin expansion, strategic portfolio simplification, innovation momentum and meaningful cost-savings delivery, while acknowledging softer top-line trends in Coatings, working capital and cash-flow pressures and remaining operational fixes at St. Louis. Overall, management presented a confident, execution-focused outlook with clear medium-term targets (mid-single-digit revenue growth, >23% operating margin, >90% three-year cash conversion), supported by sustainability and safety progress and disciplined bolt-on M&A.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
The company’s guidance under the Elevate Elementis strategy targets mid‑single‑digit revenue growth, operating margins of >23%, 3‑year operating cash conversion >90% and ROCE (ex‑goodwill) >30%; for 2026 management flags CapEx of 4–5% of revenue, a small working‑capital outflow (no factoring), and expects to be circa 1x net debt/EBITDA organically by end‑2026 (after distributing net proceeds from the pharma sale to shareholders). For context, 2025 headlines (the base year) were revenue $597.5m (‑1.9% cc), adjusted operating profit $126.7m (margin 21.2%, +150bps), adjusted EPS $0.137 (+14.2%), free cash flow $41m and adjusted operating cash flow $104.7m, with net debt $185.4m (1.3x) after returning $79.1m to shareholders (buyback + dividends) and cancelling ~4% of share capital. Management also expects further self‑help savings (delivered $18m + $6m from the new program, $4m remaining to end‑2026), to raise R&D from 2% to 3% of revenue (50% increase), to push innovation sales toward a 20% target (16.4% in 2025), to improve service metrics (On‑Time‑In‑Full half‑way to a 20% uplift) and to continue operational improvements (St. Louis debottlenecking +20% since H1, ~2/3 of the 30% opportunity).
Elementis PLC Unsponsored ADR Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is a clear strength with low leverage (debt-to-equity of 0.40) and improving stability. Cash flows are positive but declining. The primary weakness is the income statement, which shows persistent net losses and a declining revenue trend, preventing a higher score.
Income Statement
42NeutralBalance Sheet
68PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 606.65M | 598.90M | 738.30M | 713.40M | 736.40M | 709.40M |
| Gross Profit | 294.76M | 279.15M | 338.00M | 284.30M | 298.90M | 289.00M |
| EBITDA | 146.34M | 135.74M | 3.40M | 114.20M | 151.86M | 85.60M |
| Net Income | 74.02M | -45.61M | -47.80M | 26.50M | -51.10M | 2.50M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 1.11B | 1.31B | 1.51B | 1.63B | 1.84B |
| Cash, Cash Equivalents and Short-Term Investments | 86.20M | 54.60M | 59.90M | 65.80M | 54.90M | 84.60M |
| Total Debt | 264.50M | 256.60M | 253.90M | 300.90M | 453.70M | 522.70M |
| Total Liabilities | 472.30M | 470.70M | 551.40M | 664.10M | 843.10M | 935.60M |
| Stockholders Equity | 662.70M | 643.90M | 757.00M | 847.30M | 783.90M | 901.00M |
Cash Flow | ||||||
| Free Cash Flow | 38.39M | 53.02M | 62.20M | 38.60M | 29.90M | 13.60M |
| Operating Cash Flow | 64.96M | 75.38M | 100.00M | 76.80M | 77.00M | 66.70M |
| Investing Cash Flow | -21.02M | -8.32M | -37.50M | 101.10M | -46.90M | -65.00M |
| Financing Cash Flow | -18.81M | -82.69M | -59.80M | -168.00M | -57.80M | -25.30M |
Elementis PLC Unsponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELMTY, the sentiment is Positive. The current price of 10.08 is below the 20-day moving average (MA) of 10.09, above the 50-day MA of 9.69, and above the 200-day MA of 8.83, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 53.00 is Neutral, neither overbought nor oversold. The STOCH value of 3.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELMTY.
Elementis PLC Unsponsored ADR Peers Comparison
Overall Rating
IOSP72Outperform
ASH61Neutral
ELMTY58Neutral
CBT58Neutral
SCL55Neutral
MTX46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $1.92B | 13.73 | 10.42% | 2.38% | 4.73% | ― | |
| 61Neutral | $3.40B | 820.67 | 0.21% | 2.25% | 2.08% | ― | |
| 58Neutral | $1.42B | 19.46 | 11.29% | 2.33% | -8.97% | ― | |
| 58Neutral | $3.60B | 17.20 | 13.35% | 2.63% | 0.83% | -33.11% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | $1.50B | 349.05 | 0.36% | 2.40% | 10.02% | -90.50% | |
| 46Neutral | $1.86B | -27.45 | -4.12% | 0.82% | 4.76% | -19991.67% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ELMTY | Elementis PLC Unsponsored ADR | 10.08 | 2.17 | 27.40% | |
| ASH | Ashland Global Holdings, Inc. | 74.15 | 27.28 | 58.21% | |
| CBT | Cabot Corp | 70.14 | 12.83 | 22.38% | |
| IOSP | Innospec | 78.01 | 9.04 | 13.11% | |
| MTX | Minerals Technologies | 59.77 | 3.28 | 5.80% | |
| SCL | Stepan Company | 65.79 | 24.42 | 59.01% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 24, 2026
